Press Releases

Compugen Fourth Quarter and Yearend 2013 Conference Call Scheduled for Tuesday, February 11, 2014 at 10:00 AM EST

February 4, 2014

Company to discuss key 2014 corporate objectives  


Tel Aviv, Israel, February 4, 2014 — Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM  EST on Tuesday, February 11, 2014 to review fourth quarter and yearend 2013 results. During the conference call, the Company will discuss key corporate objectives for 2014 that will be disclosed in the quarterly and yearend results press release.  The quarterly and yearend results will be released on the Company’s website (, prior to the conference call.


To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-918-0609 internationally.  The call will also be available via live webcast through Compugen’s website, located at the following link.


A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-9255-918 internationally. The replay will be available through February 14, 2014


About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology.  The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company’s business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen’s corporate website at


Company contact:
Tsipi Haitovsky

Global Media Liaison
Compugen Ltd.

Tel: +972-52-598-9892